S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
OTCMKTS:BRRGF

BerGenBio ASA (BRRGF) Stock Forecast, Price & News

$1.77
0.00 (0.00%)
(As of 05/12/2023)
Compare
Today's Range
$1.77
▼
$1.77
50-Day Range
$1.77
▼
$1.77
52-Week Range
$1.77
▼
$2.35
Volume
N/A
Average Volume
200 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileAnalyst RatingsChartCompetitorsHeadlinesShort Interest

BRRGF stock logo

About BerGenBio ASA (OTCMKTS:BRRGF) Stock

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of novel medicines to treat immune-evasive, drug resistant, and metastatic cancers; and respiratory diseases. It develops bemcentinib, an oral once-a-day inhibitor of AXL receptor tyrosine kinase, which is in Phase 1b/2a clinical trial to treat non-small cell lung cancer, and Phase 2 clinical trial to treat acute myeloid leukemia and COVID-19. Bemcentinib is also being studied for glioblastoma, 2L lung cancer, melanoma, pancreatic cancer, and mesothelioma. In addition, the company is developing tilvestamab, an anti-AXL function-blocking monoclonal antibody that is in Phase 1b clinical trial for the treatment of ovarian cancer; and mipasetamab uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors. It has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.

BRRGF Price History

BRRGF Stock News Headlines

August 23, 2023 | markets.businessinsider.com
H.C. Wainwright Reaffirms Their Buy Rating on BerGenBio AS (BRRGF)
August 22, 2023 | finance.yahoo.com
BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung Cancer
September 22, 2023 | Behind the Markets (Ad)
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
August 15, 2023 | bbc.co.uk
Coronation concert ballot misleading, says regulator ASA
May 26, 2023 | finance.yahoo.com
BerGenBio ASA: Approval and publication of prospectus for the preferential Rights Issue
May 16, 2023 | markets.businessinsider.com
BerGenBio AS (BRRGF) Gets a Buy from H.C. Wainwright
April 25, 2023 | finance.yahoo.com
BerGenBio ASA: Proposed partially underwritten rights issue
March 9, 2023 | finance.yahoo.com
BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations
September 22, 2023 | Behind the Markets (Ad)
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
February 17, 2023 | finanznachrichten.de
BerGenBio ASA: BerGenBio Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC Patients
February 16, 2023 | finance.yahoo.com
BerGenBio Reports Fourth Quarter 2022 Financial Results and Provides Business Update
February 15, 2023 | finance.yahoo.com
BerGenBio Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC Patients
November 15, 2022 | finance.yahoo.com
BerGenBio reports third quarter 2022 financial results and provides business update
October 25, 2022 | prnewswire.com
BerGenBio ASA Secures NOK 100 million Shareholder Loan Facility from Meteva AS
October 11, 2022 | finance.yahoo.com
BerGenBio Announces Initiation of Phase 1b/2a Trial Evaluating Bemcentinib in 1st line Non-Small Cell Lung Cancer Patients Harboring STK11 Mutations
September 27, 2022 | finance.yahoo.com
BERGENBIO ANNOUCES FIRST PATIENT RANDOMIZED IN BEMCENTINIB TRIAL IN EU-SOLIDACT PLATFORM FOR HOSPITALIZED COVID-19 PATIENTS
September 10, 2022 | reuters.com
BGBIO.OL - Bergenbio ASA | Stock Price & Latest News | Reuters
August 23, 2022 | finance.yahoo.com
BerGenBio reports second quarter and half year 2022 financial results and provides business update
April 11, 2022 | finance.yahoo.com
BerGenBio strengthens its leadership team with appointment of Cristina Oliva as Chief Medical Officer
April 7, 2022 | finance.yahoo.com
BERGENBIO ASA: BOARD APPROVAL OF 2021 ANNUAL FINANCIAL STATEMENT AND ANNUAL REPORT 2021
February 16, 2022 | finance.yahoo.com
BERGENBIO ASA: RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2021
January 27, 2022 | finance.yahoo.com
BerGenBio and Oslo University Hospital Announce the AXL Inhibitor Bemcentinib will be Studied in the EU Funded EU-SolidAct trial in Hospitalised COVID-19 Patients
January 21, 2022 | nasdaq.com
BRRGF Real-Time Quotes
January 18, 2022 | nasdaq.com
BRRGF Price/Earnings & PEG Ratios
November 9, 2021 | finance.yahoo.com
Bergenbio Presents Pre-clinical and Clinical Data on Bemcentinib in STK11-positive NSCLC at SITC Annual Meeting 2021
November 9, 2021 | finance.yahoo.com
BerGenBio Receives FDA Fast Track Designation For Bemcentinib In STK11-mutated Advanced/Metastatic Non-small Lung Cancer (NSCLC)
July 12, 2021 | finance.yahoo.com
BerGenBio Presents Encouraging Combined Data for Bemcentinib from Two Phase II COVID-19 Studies at ECCMID
See More Headlines
Receive BRRGF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BerGenBio ASA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:BRRGF
CUSIP
N/A
CIK
N/A
Web
www.bergenbio.com
Phone
47 53 50 15 64
Fax
N/A
Employees
28
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
The Best High-Yield Dividend Stocks for 2023 Cover
The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Martin Olin (Age 54)
    Chief Exec. Officer
    Comp: $863.23k
  • Mr. Rune Skeie (Age 50)
    Chief Financial Officer
    Comp: $235.5k
  • Dr. James Barnes Ph.D.
    Chief Operating Officer
  • Ms. Gayle M. Mills M.B.A (Age 68)
    Chief Bus. Officer
  • Ms. Cristina Oliva M.D.
    Chief Medical Officer
  • Graham Morell
    Head of IR
  • Dr. Akil Jackson
    Medical Director

Key Competitors

View All Competitors













BRRGF Stock - Frequently Asked Questions

Should I buy or sell BerGenBio ASA stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BerGenBio ASA in the last year. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BRRGF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BRRGF, but not buy additional shares or sell existing shares.
View BRRGF analyst ratings or view top-rated stocks.

How have BRRGF shares performed in 2023?

BerGenBio ASA's stock was trading at $1.77 at the start of the year. Since then, BRRGF shares have increased by 0.0% and is now trading at $1.77.
View the best growth stocks for 2023 here.

Are investors shorting BerGenBio ASA?

BerGenBio ASA saw a decrease in short interest during the month of August. As of August 31st, there was short interest totaling 241,000 shares, a decrease of 90.2% from the August 15th total of 2,463,000 shares. Based on an average daily volume of 200 shares, the short-interest ratio is presently 1,205.0 days.
View BerGenBio ASA's Short Interest.

What is BerGenBio ASA's stock symbol?

BerGenBio ASA trades on the OTCMKTS under the ticker symbol "BRRGF."

How do I buy shares of BerGenBio ASA?

Shares of BRRGF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BerGenBio ASA's stock price today?

One share of BRRGF stock can currently be purchased for approximately $1.77.

How can I contact BerGenBio ASA?

BerGenBio ASA's mailing address is Jonas Lies Vei 91, Bergen, Hordaland 5009. The official website for the company is www.bergenbio.com. The company can be reached via phone at 47 53 50 15 64.

This page (OTCMKTS:BRRGF) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -